Gilead Sciences | The Together Campaign
See you at CROI 2026
In the face of new challenges in HIV, Gilead is more committed than ever in advancing the science to fight it.
let’s talk
About ending the HIV Epidemic
Conference on Retroviruses and Opportunistic Infections (CROI)
Denver, Colorado.
For decades, Gilead has led global virology research, turning once-fatal diseases into manageable or preventable conditions. From pioneering the first single-tablet treatment regimen for HIV to launching the only twice-yearly prevention option, we are setting new milestones in treatment and prevention with therapies that significantly improve outcomes for people living with HIV or individuals who need or want PrEP.
Today, we’re building on our legacy in virology, developing long-acting and person-centered options for HIV treatment and prevention while working together with community partners to help end the epidemic.
We won’t rest until the HIV epidemic has ended. Let’s talk.
Come visit Gilead at CROI 2026 in Denver, CO.
Working to end the epidemic.
See what’s coming down the pipeline.
*As reported in Gilead's Q3 2025 Earnings Statement.
Subject to Gilead and Merck co-development and co-commercialization agreement. 2. Teropavimab andzinlirvimab are broadly neutralizing antibody (bNAbs). 3. Non-Gilead sponsored trial(s) ongoing. HIV – human immunodeficiency virus, INSTI – integrase strand transfer inhibitor, LAI – long-acting injectable, LAO – long-acting oral, NDA – new drug application, NRTTI – nucleoside reverse transcriptase translocation inhibitor, PrEP – pre-exposure prophylaxis, FPI – first patient in.
GILEAD, the GILEAD logo, the & design and the Creating Possible tagline are registered trademarks of Gilead Sciences, Inc. © 2026 Gilead Sciences, Inc. All rights reserved. GFM-UNB-2075. Date of preparation January 2026. This content was developed and funded by Gilead Sciences, Inc.